Carla Casulo MD

PubMed

• Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
  Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L Ulrickson
  Journal of Clinical Oncology. 2025-11-20
• Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.
  Nadia Toumeh, Melissa Larson, Brianna Negaard, Carla Casulo, Sairah Ahmed
  Leukemia & Lymphoma. 2025-11-03
• Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort.
  James R Cerhan, Tereza Sokolova, Elliott J Cahn, Mazie Tsang, Christopher S Strouse
  Hematological Oncology. 2025-11-01

Journal Articles

• Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial  
  Andrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood

Abstracts/Posters

• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
  Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
  Carla Casulo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The effect of duvelisib, a dual inhibitor of PI3K-I on components of the tumor microenvironment in previously untreated follicular lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018